ALEXANDRIA, Egypt - Wednesday, November 4th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, will present advanced results of the abstract entitled: High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial.
The late-breaker, oral presentation will take place on Monday, November 16, 2015 at the Moscone West Convention Center in San Francisco, CA at 3:45PM.
ABOUT PHARCO
Pharco Pharmaceuticals, Inc. is the largest manufacturer of pharmaceuticals in Egypt, focused on research, formulation, manufacturing and commercialisation of pharmaceutical products in the MENA region. Today Pharco employs over 8,000 employees, and has over 500M product sales units—ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 47 countries around the world. Pharco works towards one goal…to provide highly effective and safe pharmaceutical products to patients at an affordable price. Pharco licensed ravidasvir hydrochloride (formerly known as PPI-668) from Presidio Pharmaceuticals, a San Francisco-based clinical stage, specialty pharmaceutical company.
For more information, please visit our website at: www.pharco.org
ABOUT PRESIDIO
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s current focus is on effective therapies for HCV infection, and includes pan-genotypic inhibitors of NS5A (ravidasvir) and NS5B (PPI-383).
For more information on ravidasvir, please visit www.presidiopharma.com
Contacts
EEPI – Pharco Corporation
Hanaa Abdel-Maguid
Medical Director
hepc@pharco.org
or
Pharco Pharmaceuticals, Inc.
Leo J. Redmond, 415-655-7560
Chief Financial Officer & Acting President
lredmond@presidiopharma.com
Permalink: http://me-newswire.net/news/16242/en
(BUSINESS WIRE)-- Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, will present advanced results of the abstract entitled: High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial.
The late-breaker, oral presentation will take place on Monday, November 16, 2015 at the Moscone West Convention Center in San Francisco, CA at 3:45PM.
ABOUT PHARCO
Pharco Pharmaceuticals, Inc. is the largest manufacturer of pharmaceuticals in Egypt, focused on research, formulation, manufacturing and commercialisation of pharmaceutical products in the MENA region. Today Pharco employs over 8,000 employees, and has over 500M product sales units—ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 47 countries around the world. Pharco works towards one goal…to provide highly effective and safe pharmaceutical products to patients at an affordable price. Pharco licensed ravidasvir hydrochloride (formerly known as PPI-668) from Presidio Pharmaceuticals, a San Francisco-based clinical stage, specialty pharmaceutical company.
For more information, please visit our website at: www.pharco.org
ABOUT PRESIDIO
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s current focus is on effective therapies for HCV infection, and includes pan-genotypic inhibitors of NS5A (ravidasvir) and NS5B (PPI-383).
For more information on ravidasvir, please visit www.presidiopharma.com
Contacts
EEPI – Pharco Corporation
Hanaa Abdel-Maguid
Medical Director
hepc@pharco.org
or
Pharco Pharmaceuticals, Inc.
Leo J. Redmond, 415-655-7560
Chief Financial Officer & Acting President
lredmond@presidiopharma.com
Permalink: http://me-newswire.net/news/16242/en
No comments:
Post a Comment